Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Northland’s Baltic Power Offshore Wind Project Completes Installation of All 76 TurbinesNorthland Power Inc. ("Northland" or the "Company") (TSX: NPI) today announced the completion of turbine installation at Baltic Power, the 1.1 GW offshore wind project in Poland jointly owned by Northland and ORLEN. All 76 turbines are now installed, with over one-third currently generating power. The project is advancing through commissioning and is on track for commercial operations in 2026, with costs aligned with original expectations. Baltic Power achieved first power in July 2026, delivering the first electricity ever generated from offshore wind to Poland’s national grid.
- Myriad Uranium Corp.Myriad Uranium Re-Assumes 100% Control of High-Grade Breccia Pipes Near Pinyon Plain Mine, Terminates Wedgemount OptionMyriad Uranium Corp. (CSE: M) (OTCQB: MYRUF) (FSE: C3Q) ("Myriad" or the "Company") announces that it has terminated its option agreement with Wedgemount Resources Corp. ("Wedgemount") relating to the Company's Arizona Breccia Pipe Project, executed on June 9, 2026, re-assuming 100% ownership of the portfolio of 24 individual breccia pipe prospects. The breccia pipes share key geological characteristics with Energy Fuels' nearby...
- ITM and Lumara Bio to Announce New Data for ¹⁷⁷Lu-edotreotide (ITM-11) and Ga-DPI-4452 at EANM 2026Garching / Munich, October 7, 2026 — ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Lumara Bio, a dedicated oncology therapeutics division of ITM, today announced that new data for 177Lu-edotreotide (ITM-11) and Ga-DPI-4452 (CA-IX peptide) will be unveiled in two top-rated oral presentations at the European Association of Nuclear Medicine (EANM) Congress, held from October 17 – 21, 2026 in Vienna, Austria. Anthime Flaus, MD, PhD, of the Hospital Louis Pradel in Bron, France will present dose-response findings from the Phase 3 COMPETE trial, in which patients with gastroenteropancreatic neuroendocrine tumors were treated with 177Lu-edotreotide. Alina Küper, MD, of the University Hospital Essen in Germany will present interim results from an independent, retrospective analysis of the PET/CT imaging agent Ga-DPI-4452 (CA-IX peptide) used for the imaging of clear cell renal cell carcinoma in a bicenter registry. In addition to the scientific presentations, ITM will host a booth reception and separate Meet the Expert session. At this session, Dr. Neil Quigley will share insights into the production of Actinium-225 (225Ac) using medium-energy cyclotrons and present Actineer’s approach to increase production capacity. Actineer is the joint venture between ITM and Canadian Nuclear Laboratories. Oral Presentation Details Title: Ga-DPI-4452 (CA-IX peptide) PET/CT for Imaging Clear Cell Renal Cell Carcinoma: Interim Results from a Bicentre Registry Session Title: Renal Cell Cancer and Novel Targets Session Number: 506 Track: Clinical Oncology Date and Time: Sunday, October 18, 2026, 15:00 – 16:30 CEST Location: Hall C Presenter: Dr. Alina Küper, University Hospital Essen, Essen, Germany Title: Dose-response Analysis in Patients with Gastroenteropancreatic Neuroendocrine Tumors Receiving [¹⁷⁷Lu]Lu-edotreotide Session Title: From Clinical Dosimetry to Treatment Adaptation in [¹⁷⁷Lu] Therapy Session Number: 1505 Track: Cutting Edge Science Date and Time: Tuesday, October 20, 2026, 15:00 – 16:30 CEST Location: Hall B Presenter: Dr. Anthime Flaus, Hospital Louis Pradel, Bron, France Meet the Expert Session Title: 225Ac Production via Medium-Energy Cyclotrons: Actineer’s Path Towards Increasing Production Capacities Date and Time: Monday, October 19, 2026, 10:30 – 10:50 CEST Location: ITM Booth #415, Hall X4 Presenter: Dr. Neil Quigley, Radioisotope Scientific Expert at ITM Conference attendees will have the opportunity to learn more about ITM and Lumara Bio, a division of ITM, by visiting the company booth, #415 in Hall X4. Attendees are also invited to join the ITM team for an informal booth reception and networking opportunity on Monday, October 19, from 16:00 to 17:00 CEST. 177Lu-edotreotide (ITM-11) and Ga-DPI-4452 (CA-IX peptide) are investigational products and are not approved by any regulatory authority for the safety and/or efficacy of any intended use. About the COMPETE Trial The COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide (ITM-11), a proprietary, synthetic, targeted radiotherapeutic investigational agent compared to everolimus, a targeted molecular therapy, in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This trial met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival (PFS) compared to everolimus. 177Lu-edotreotide is an investigational product and is not approved by any regulatory authority for the safety and/or efficacy of any intended use. 177Lu-edotreotide is also being evaluated in COMPOSE, a Phase 3 study in patients with well-differentiated, aggressive Grade 2 or Grade 3, somatostatin receptor (SSTR)-positive GEP-NETs. About Ga-DPI-4452 (ITM-94) Ga-DPI-4452 (also known as [68Ga]Ga-DPI-4452, CA-IX peptide, or ITM-94) is an investigational gallium-68-radiolabeled PET imaging agent targeting carbonic anhydrase IX (CAIX), a cell surface protein that plays a key role in tumor growth, invasion, and metastasis. ITM-94 is designed to non-invasively improve the characterization of indeterminate renal masses and enable more accurate diagnosis and disease staging of clear cell renal cell carcinoma (ccRCC). ITM-94 received Fast Track Designation from the FDA in October 2025. [68Ga]Ga-DPI-4452 is an investigational product and is not approved by any regulatory authority for the safety and/or efficacy of any intended use. About ITM Isotope Technologies Munich SE ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com About Lumara Bio Lumara Bio, a division of ITM, builds on more than two decades of radiopharmaceutical expertise and is advancing a focused pipeline of targeted therapies for cancers where treatment options remain limited. https://lumarabio.com ITM Contact Corporate Communications Kathleen Noonan/Julia Westermeir Phone: +49 89 329 8986 1500 Email: [email protected] Investor Relations Ben Orzelek Phone: +49 89 329 8986 1009 Email: [email protected]
- Global Power Discrete Market Size, Share, Trends, and Forecast (2021 - 2034) | Market to Reach US$ 24.46 Billion at 6.4% CAGR, Fueled by SiC, GaN, EVs, and Data CentersCapitalize on EVs, 5G, IoT and Industry 4.0 by prioritizing energy-efficient SiC/GaN solutions and Asia Pacific’s robust semiconductor ecosystem.
- Chile Data Center Colocation Market - Supply and Demand Analysis, Size, Share, and Forecast 2026-2031 | AI, Cloud, and Hyperscale Investment Fuel 15.47% CAGRChile’s colocation market benefits from cloud and AI adoption, stronger fiber and subsea links, streamlined permits, renewable energy, and water-efficient cooling
- VAALCO Energy, Inc.VAALCO Energy, Inc. Announces Positive Operational UpdatesVAALCO Energy, Inc. (NYSE: EGY, LSE: EGY) (“Vaalco” or the “Company”) announced successful completion of the offshore Gabon Phase 3 drilling program, including encouraging initial well results on the ETSEM-3H well and demobilization of the rig from the SE Etame platform. Additionally, the Company provided updates on the recently commenced Baobab drilling program offshore Côte d’Ivoire.
- Valeura Energy Inc.Valeura Energy Inc.: Q3 2026 Operations UpdateValeura Energy Inc. (TSX:VLE, OTCQX:VLERF) (“Valeura” or the “Company”) provides an operations and financial update for Q3 2026.
- Hagens Berman Sobol Shapiro LLPHagens Berman Alerts Fluence Energy (FLNC) Investors to Securities Fraud Class Action and Encourages Investors with Losses to Contact the FirmFluence Energy (NASDAQ: FLNC) faces a securities class action, which seeks to represent investors who purchased or otherwise acquired Fluence securities between November 24, 2025 and September 16, 2026. The suit follows a stream of unexpected...
- Scage FutureScage Future Announces Plan to Implement ADS Ratio ChangeScage Future ("Scage Future" or the "Company") (Nasdaq: SCAG), a zero-emission solution provider of new energy heavy-duty commercial vehicles and e-fuel solutions, today announced that it plans to change the ratio of its American Depositary...
- Terra Clean Energy Announces Closing of Oversubscribed $2.4 Million Financing Led by Centurion One CapitalNot for distribution to U.S. newswire services or for release, publication, distribution or dissemination, directly or indirectly, in whole or in part, into the United States
- Maximize Market Research Pvt. Ltd.Global Smart Refrigerator Market Set to Reach USD 14.30 Billion by 2034 as AI Integration, Connected Home Adoption and Energy-Efficient Technologies Accelerate, reports Maximize Market ResearchThe Global Smart Refrigerator Market was valued at USD 5.28 Billion in 2025 and is projected to grow at a CAGR of 11.7% from 2026 to 2034, reaching USD 14.30 Billion by 2034, according to a new analysis by Maximize Market Research. Explore 120...
- Bronstein, Gewirtz & Grossman LLC Urges Fluence Energy, Inc Investors to Act: Class Action Filed Alleging Investor HarmNew class action for Fluence (FLNC) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/30/2026